← Leaderboards
Philippe Leboulch
Yeshiva University
$5,901,573
Attributed
$5,901,573
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $668.1K · FY2005–11$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$5,901,573 · 5
By mechanism
R01$3,292,775 · 2
P01$2,133,048 · 2
R21$475,750 · 1
Top collaborators
No co-investigators on record.
Most similar at Yeshiva University
Same institution · by research overlap
- Charles E. Rogler$8,389,911
- Seetharama A Acharya$4,285,000
- Ronald L Nagel$7,416,455
- Eric Bauhassira$1,066,524
- Nadrian C. Seeman$4,094,897
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapySickle Cell AnemiaTransfection /Expression VectorBiotechnologyHematopoietic Stem CellsGlobinChimeric ProteinsThalassemiaLentivirusMouse ModelBaseNovel StrategiesLentivirus VectorMagnetic FieldIn VitroHereditary DiseaseIn VivoClinical ApplicationGene ExpressionGenesCellsCellular TransductionCd34 GeneClinical Trials
Grant awards (19)
Cell selection strategies for the gene therapy of the beta-hemoglobinopathies$403,674
R01 · FY2011 · HL · contact PI
Cell selection strategies for the gene therapy of the beta-hemoglobinopathies$415,742
R01 · FY2010 · HL · contact PI
Cell selection strategies for the gene therapy of the beta-hemoglobinopathies$424,226
R01 · FY2009 · HL · contact PI
Cell selection strategies for the gene therapy of the beta-hemoglobinopathies$424,226
R01 · FY2008 · HL · contact PI
Novel Lentiviral Packaging Systems$243,870
R01 · FY2008 · DK · contact PI
Novel Lentiviral Packaging Systems$333,762
R01 · FY2007 · DK · contact PI
Novel Lentiviral Packaging Systems$344,251
R01 · FY2006 · DK · contact PI
Novel Lentiviral Packaging Systems$353,049
R01 · FY2005 · DK
Novel Lentiviral Packaging Systems$349,975
R01 · FY2004 · DK
Semi-Synthetic, Site-Specifically Integrating Lentivirus$216,250
R21 · FY2004 · EB
Semi-Synthetic, Site-Specifically Integrating Lentivirus$259,500
R21 · FY2003 · EB
SILENCING RESISTANT GLOBIN RETROVIRAL VECTORS$266,631
P01 · FY2002 · HL
CORE--VIRUS$266,631
P01 · FY2002 · HL
CORE--VIRUS$266,631
P01 · FY2002 · HL
SILENCING RESISTANT GLOBIN RETROVIRAL VECTORS$266,631
P01 · FY2002 · HL
CORE--VIRUS$266,631
P01 · FY2001 · HL
SILENCING RESISTANT GLOBIN RETROVIRAL VECTORS$266,631
P01 · FY2001 · HL
CORE--VIRUS$266,631
P01 · FY2000 · HL
SILENCING RESISTANT GLOBIN RETROVIRAL VECTORS$266,631
P01 · FY2000 · HL